← All trials
NCT05180968
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Jan 6, 2022
- Last posted
- May 18, 2022
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ManitobaLead sponsor
- University of ManitobaOverall official - principal investigator
- University of ManitobaReponsible party - principal investigator
- McMaster UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.